Cardiotoxicity of Radiation Therapy (CTRT)
Status: | Completed |
---|---|
Conditions: | Breast Cancer, Lung Cancer, Cancer, Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 1/11/2019 |
Start Date: | June 2, 2015 |
End Date: | November 26, 2018 |
The overall objective of this proposal is to determine the utility of sensitive imaging and
biomarker measures in detecting subclinical cardiotoxicity across a spectrum of radiation
doses to the heart. We will focus specifically on patients receiving photon or proton chest
radiotherapy. Our broad working hypothesis is that RT induces early, subclinical CV injury,
as evidenced by cardiomyocyte inflammation and necrosis, and worsening CV function.
biomarker measures in detecting subclinical cardiotoxicity across a spectrum of radiation
doses to the heart. We will focus specifically on patients receiving photon or proton chest
radiotherapy. Our broad working hypothesis is that RT induces early, subclinical CV injury,
as evidenced by cardiomyocyte inflammation and necrosis, and worsening CV function.
Inclusion Criteria:
- Age 18 years or older.
- Patients with left sided breast cancer newly initiating fractionated whole
breast/chest wall with regional nodal photon or proton radiation therapy.
- Patients with right sided breast cancer with newly initiating fractionated photon or
proton radiation therapy with mediastinal nodal proton or photon radiation therapy
that will include cardiac dose.
- Lung cancer patients treated with definitive intent (greater than or equal to 50 Gy)
using fractionated thoracic radiotherapy with proton or photon radiation therapy.
Patients receiving concurrent chemotherapy will be allowed.
- Patients with mediastinal lymphoma, whose lowest extent of mediastinal disease is at
or below the level of the carina, treated with consolidative radiation with definitive
intent (greater than or equal to 20 Gy) using fractionated thoracic radiotherapy with
proton or photon radiation therapy.
- Ability to read and comprehend English.
Exclusion Criteria:
- Prior radiotherapy to the region of the study cancer that would result in overlap of
radiation therapy fields
- Patients receiving stereotactic body radiotherapy
- Patients unable to undergo MR imaging will be excluded from the optional MR, but will
not be excluded from the main study.
- Life expectancy less than 12 months
- Vulnerable patients as noted in 5 below (children, pregnant women, fetuses, neonates,
or prisoners)
- Patients with estimated glomerular filtration rate of less than 60 ml/min/1.73sq.m
will be excluded from the optional MR, but will not be excluded from the main study.
- Non-diagnostic echocardiography windows
We found this trial at
1
site
3400 Civic Center Blvd
Philadelphia, Pennsylvania 19104
Philadelphia, Pennsylvania 19104
(215) 662-6065
Principal Investigator: Bonnie Ky, MD
Phone: 855-216-0098
Abramson Cancer Center of the University of Pennsylvania The Abramson Cancer Center of the University...
Click here to add this to my saved trials